Evidence challenging the National Institute for Health and Clinical Excellence’s decision to restrict access to dementia drugs on the NHS has been submitted to the High Court.
The Alzheimer’s Society’s dossier claims that Nice “drastically underestimated” costs of care and “overlooked” benefits of drugs to carers.
The charity also claims the healthcare advisory body “ignored the way the decision would grossly discriminate against people of different cultural and educational backgrounds.”
Last month, the High Court agreed to challenge the ruling made by Nice after an application for judicial review was made by pharmaceutical drugs manufacturer Eisai Limited.
It will be the first ever judicial review of Nice, which ruled that all drug treatments for Alzheimer’s disease should not be prescribed on the NHS because of cost. Nice changed its position to allow limited access to treatment following widespread opposition.
Neil Hunt, chief executive of the Alzheimer’s Society, said: “The evidence we are presenting highlights serious flaws in the process Nice have used. The decision is a blow for millions of people already devastated by Alzheimer’s disease. We have been left with no choice but to champion the rights of people with dementia and their carers in the high court.”
A court date has not been set.
Related items
Alzheimer’s drug appeal rejected
Alzheimer’s Society
Homeward bound
18 September 2003
Beware signs of decline
08 May 2003
House of the chastising son
20 March 2003
Jersey: Simon Bellwood 'unfairly sacked' inquiry finds
Councils failing to implement government guidance issued in 2002, study says
Threat of action called off until September in bid to end dispute
Lone parents, disabled and drug users face tougher benefits regime
Private Member Bills
25 July 2008
Government Legislation
25 July 2008
Details of government consultations
25 July 2008
